CN115531337A - 一种复方氨溴特罗缓释片及其制备方法 - Google Patents
一种复方氨溴特罗缓释片及其制备方法 Download PDFInfo
- Publication number
- CN115531337A CN115531337A CN202211264219.3A CN202211264219A CN115531337A CN 115531337 A CN115531337 A CN 115531337A CN 202211264219 A CN202211264219 A CN 202211264219A CN 115531337 A CN115531337 A CN 115531337A
- Authority
- CN
- China
- Prior art keywords
- tablet
- release
- compound
- luo
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 17
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 title claims abstract description 13
- 229960005174 ambroxol Drugs 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title abstract description 22
- 239000003826 tablet Substances 0.000 claims abstract description 43
- 229960001399 clenbuterol hydrochloride Drugs 0.000 claims abstract description 42
- OPXKTCUYRHXSBK-UHFFFAOYSA-N clenbuterol hydrochloride Chemical compound Cl.CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 OPXKTCUYRHXSBK-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229960000985 ambroxol hydrochloride Drugs 0.000 claims abstract description 37
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 claims abstract description 36
- 238000002156 mixing Methods 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000000853 adhesive Substances 0.000 claims abstract description 15
- 230000001070 adhesive effect Effects 0.000 claims abstract description 15
- 239000000314 lubricant Substances 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 12
- 238000013268 sustained release Methods 0.000 claims abstract description 12
- 239000012730 sustained-release form Substances 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 239000007939 sustained release tablet Substances 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 36
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 34
- -1 compound ambroxide Chemical class 0.000 claims description 18
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 18
- 235000019359 magnesium stearate Nutrition 0.000 claims description 17
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 14
- 230000001965 increasing effect Effects 0.000 claims description 14
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 14
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 14
- 229940069328 povidone Drugs 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000007888 film coating Substances 0.000 claims description 11
- 238000009501 film coating Methods 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 10
- 239000004203 carnauba wax Substances 0.000 claims description 9
- 235000013869 carnauba wax Nutrition 0.000 claims description 9
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 9
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
- 239000001856 Ethyl cellulose Substances 0.000 claims description 7
- 229920001249 ethyl cellulose Polymers 0.000 claims description 7
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 229960003943 hypromellose Drugs 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000007779 soft material Substances 0.000 claims description 5
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 229940049654 glyceryl behenate Drugs 0.000 claims description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 239000003405 delayed action preparation Substances 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229960000541 cetyl alcohol Drugs 0.000 claims description 2
- 229960004667 ethyl cellulose Drugs 0.000 claims description 2
- 125000005908 glyceryl ester group Chemical group 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims description 2
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 229960004274 stearic acid Drugs 0.000 claims description 2
- 229940012831 stearyl alcohol Drugs 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 229960001117 clenbuterol Drugs 0.000 abstract description 4
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000000857 drug effect Effects 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000005550 wet granulation Methods 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 description 28
- 238000000576 coating method Methods 0.000 description 28
- 238000004090 dissolution Methods 0.000 description 14
- 238000005303 weighing Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 208000006673 asthma Diseases 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 238000007865 diluting Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 239000012088 reference solution Substances 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 208000014085 Chronic respiratory disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- YPZUZOLGGMJZJO-LQKXBSAESA-N ambroxan Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C)[C@@H]1[C@]2(C)OCC1 YPZUZOLGGMJZJO-LQKXBSAESA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical group CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 239000005696 Diammonium phosphate Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000614 adrenergic beta-2 receptor agonist Substances 0.000 description 1
- 229940124627 adrenergic β2 receptor agonist Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 235000019838 diammonium phosphate Nutrition 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种复方氨溴特罗缓释片及其制备方法。本发明采用熔融制粒工艺或湿法制粒工艺,制备的样品缓释效果更佳,同时解决制剂中盐酸克仑特罗混合不均匀的问题,工艺易于控制;本发明复方克仑特罗缓释片处方组成为盐酸氨溴索、盐酸克仑特罗、缓释骨架、粘合剂和润滑剂,该处方组成使服用本品后盐酸氨溴索和盐酸克仑特罗均缓慢释放,维持较平稳的释药速度和较持久的药效,减少毒副作用,适合临床需求。
Description
技术领域
本发明涉及药物制剂领域,具体涉及一种复方氨溴特罗缓释片及其制备方法。
背景技术
呼吸系统疾病是一种常见病、多发病,在世界范围内都有较高的发病率,且有增加的趋势,它是我国人口死亡的第二大因素。呼吸系统疾病的主要症状为咳嗽、咳痰及哮喘,但临床上可供选择的药物并不多且起效较慢。
盐酸氨溴索,化学名为2-氨基-3,5-二溴-N-(反式-4-羟基环己基)苄胺,为白色至微黄色结晶性粉末,几乎无臭。祛痰药,有良好的黏痰溶解作用及润滑呼吸道作用,可促进肺表面活性物质的分泌、呼吸液的分泌和纤毛运动等。用于急慢性呼吸道疾病、支气管分泌异常等的治疗。本品具有粘液排除促进作用及溶解分泌物的特性,它可促进呼吸道内部粘稠分泌物的排除及减少粘液的滞留,因而显著促进排痰,改善呼吸状况。应用本品治疗时,病人粘液的分泌可恢复至正常状况。咳嗽及痰量通常显著减少,呼吸道粘膜上的表面活性物质因而能发挥其正常的保护功能。半衰期7-12小时,未发现蓄积,主要由肝脏代谢,90%由肾脏清除。
盐酸克仑特罗是一种强效的选择性肾上腺素β2受体激动剂,能够舒张支气管平滑肌,其支气管扩张作用比舒喘灵强100倍,而对心血管系统影响微弱。除平喘外,盐酸克仑特罗还具有增强支气管纤毛活动能力、促进痰液排出,有助于提高平喘疗效。盐酸克仑特罗用于呼吸系统疾病治疗具有起效快、维持时间长、适用剂量小、毒副作用低等特点。
将平喘药盐酸克仑特罗和祛痰药盐酸氨溴索所组成的复方制剂,可同时发挥祛痰止咳及抗哮喘的功效,用于止咳、化痰、平喘。上述复方制剂目前国内已有上市,如复方氨溴索片、氨溴特罗口服液等。这些制剂的缺点是其为普通复方制剂,作用时间短,一天需给药2~3次,患者顺应性较差;而且血药浓度波动,易引起不良反应。
因此,为了克服上述缺点,研究同时具有止咳、平喘及祛痰双重功效并具有缓释效果的药物,用于改善患者的肺部功能指标特别是对于慢性呼吸系统疾病的治疗,具有十分重要的意义。
发明内容
本发明提供一种复方氨溴特罗缓释片,其素片组成成分按重量份数计包括以下组分:75份盐酸氨溴索、0.05份盐酸克仑特罗、40~60份缓释骨架、8~12份粘合剂和2.7~3.3份润滑剂。
在一些实施方案中,所述的复方氨溴特罗缓释片,其素片组成成分按重量份数计包括以下组分:75份盐酸氨溴索、0.05份盐酸克仑特罗、50份缓释骨架、10份粘合剂和3份润滑剂。
在一些实施方案中,所述的缓释骨架选自羟丙甲纤维素、聚维酮、乙基纤维素、甲基纤维素、羟乙基纤维素、十六烷醇、十八烷醇、山榆酸甘油酯、硬脂酸、单硬脂酸、甘油酯、巴西棕榈蜡、羧甲基纤维素钠、聚乙烯醇、甲壳素壳多糖中的一种或多种组合。
在一些典型的实施方案中,所述的缓释骨架选自羟丙甲纤维素、乙基纤维素、巴西棕榈蜡或十八烷醇中的一种或多种组合。
在一些实施方案中,所述的粘合剂选自甲基纤维素、乙基纤维素、羟丙纤维素、羟丙甲纤维素、聚维酮或淀粉的一种或多种组合。
在一些典型实施方案中,所述的粘合剂选自聚维酮。
在一些实施方案中,所述的润滑剂选自硬脂酸、氢化植物油、山嵛酸甘油酯、聚乙二醇4000、聚乙二醇6000、硬脂酸镁、月桂醇硫酸镁、滑石粉或微粉硅胶中的一种或多种组合。
在一些典型实施方案中,所述的润滑剂选自硬脂酸镁。
在一些实施方案中,所述的复方氨溴特罗缓释片,其素片组成成分如下:
在一些实施方案中,所述的复方氨溴特罗缓释片,其素片组成成分如下:
在一些实施方案中,所述的复方氨溴特罗缓释片,其素片组成成分如下:
另一方面,本发明提供了所述的缓释制剂的制备方法,其包括以下步骤:
(1)将缓释骨架加热至熔融,温度控制60℃~100℃;
(2)将过筛后处方量的原料药加入熔融后的缓释骨架材料中搅拌均匀;
(3)将熔融混合物冷却,1.2mm筛网整粒;
(4)加入处方量的粘合剂、润滑剂混合均匀;
(5)压片;
(6)具有避光的薄膜包衣剂包衣。
优选地,所述步骤(1)中温度控制在90℃~100℃。
另一方面,本发明提供了所述的缓释制剂的另一种制备方法,其包括以下步骤:
1)将粘合剂配制成水溶液中,备用;
2)将处方量的盐酸氨溴索、盐酸克仑特罗和缓释骨架等量递增方式混合均匀,于湿法制粒机内边搅拌边加入粘合液,粘合液加入结束后继续制粒1~2min;
3)将制备的软材经18目筛制粒,置于烘箱内40~60℃干燥至水分低于4%;
4)干燥后的颗粒经24目筛整粒;
5)加入处方量的硬脂酸镁,混合均匀;
6)压片;
7)具有避光的薄膜包衣剂包衣。
本发明的有益效果:本发明的目的是提供一种复方氨溴特罗缓释片,它是具有止咳、祛痰及平喘多重功效的药物,与氨溴特罗片和氨溴特罗口服溶液相比较,由于本剂型缓慢释放的特点,可以持续在24小时内释药,从而维持较为平稳的血药浓度和更长的作用时间,具有毒副作用减小、服用更加方便的优点。因此,开发研制本品必将取得广泛的社会效益和经济效益。
具体实施方式
以下结合具体实施方式对本发明作进一步详细说明。应该强调的是:下述说明仅仅是示例性的,而本发明不受以下实施例的范围限制,实施例中采用的实施条件可以根据具体要求做进一步调整。
实施例1
盐酸氨溴索 | 75mg |
盐酸克仑特罗 | 0.05mg |
羟丙甲纤维素-K100M | 50mg |
聚维酮 | 10mg |
硬脂酸镁 | 3mg |
制备工艺:(1)将处方量的盐酸氨溴索、盐酸克仑特罗、聚维酮和缓释骨架置于等量增重混合方式混合均匀,(2)加入处方量的硬脂酸镁,混合均匀;(3)压片,采取本领域常用的压片方法;(4)称取薄膜包衣剂(胃溶型),并分别溶解于处方量的蒸馏水中,混合均匀形成包衣液,素片置包衣锅内包衣,即得具有复方氨溴特罗缓释片,包衣增重3-5%。
实施例2
盐酸氨溴索 | 75mg |
盐酸克仑特罗 | 0.05mg |
乙基纤维素(100cp) | 50mg |
聚维酮水溶液 | 10mg |
硬脂酸镁 | 3mg |
制备工艺同实施例1。
实施例3
盐酸氨溴索 | 75mg |
盐酸克仑特罗 | 0.05mg |
巴西棕榈蜡 | 20mg |
十八烷醇 | 30mg |
聚维酮 | 10mg |
硬脂酸镁 | 3mg |
制备工艺同实施例1。
实施例4
盐酸氨溴索 | 75mg |
盐酸克仑特罗 | 0.05mg |
巴西棕榈蜡 | 20mg |
十八烷醇 | 30mg |
聚维酮 | 10mg |
硬脂酸镁 | 3mg |
制备工艺:(1)将粘合剂配制成质量分数为2-3%的水溶液中,备用;(2)将处方量的盐酸氨溴索、盐酸克仑特罗和缓释骨架等量递增方式混合均匀,于湿法制粒机内边搅拌边加入粘合液,粘合液加入结束后继续制粒1~2min;(3)将步骤(2)制备的软材经18目筛制粒,置于烘箱内40℃干燥至水分低于4%;(4)干燥后的颗粒经24目筛整粒;(5)加入处方量的硬脂酸镁,混合均匀;(6)压片;(7)称取薄膜包衣剂(胃溶型),并分别溶解于处方量的蒸馏水中,混合均匀形成包衣液,素片置包衣锅内包衣,即得具有复方氨溴特罗缓释片,包衣增重3-5%。
实施例5
制备工艺:(1)将粘合剂配制成水溶液中,备用;(2)将处方量的盐酸氨溴索、盐酸克仑特罗和缓释骨架等量递增方式混合均匀,于湿法制粒机内边搅拌边加入粘合液,粘合液加入结束后继续制粒1~2min;(3)将制备的软材经18目筛制粒,置于烘箱内50℃干燥至水分低于4%;(4)干燥后的颗粒经24目筛整粒;(5)加入处方量的硬脂酸镁,混合均匀;(6)压片;(7)称取避光型薄膜包衣剂(胃溶型),并分别溶解于处方量的蒸馏水中,混合均匀形成包衣液,素片置包衣锅内包衣,即得具有复方氨溴特罗缓释片,包衣增重3-5%。
实施例6
盐酸氨溴索 | 75mg |
盐酸克仑特罗 | 0.05mg |
巴西棕榈蜡 | 20mg |
十八烷醇 | 30mg |
聚维酮水溶液 | 10mg |
硬脂酸镁 | 3mg |
制备工艺:(1)将粘合剂配制成水溶液中,备用;(2)将处方量的盐酸氨溴索、盐酸克仑特罗和缓释骨架等量递增方式混合均匀,于湿法制粒机内边搅拌边加入粘合液,粘合液加入结束后继续制粒1~2min;(3)将制备的软材经18目筛制粒,置于烘箱内60℃干燥至水分低于4%;(4)干燥后的颗粒经24目筛整粒;(5)加入处方量的硬脂酸镁,混合均匀;(6)压片;(7)称取避光型薄膜包衣剂(胃溶型),并分别溶解于处方量的蒸馏水中,混合均匀形成包衣液,素片置包衣锅内包衣,即得具有复方氨溴特罗缓释片,包衣增重3-5%。
实施例7
盐酸氨溴索 | 75mg |
盐酸克仑特罗 | 0.05mg |
巴西棕榈蜡 | 20mg |
十八烷醇 | 30mg |
聚维酮水溶液 | 10mg |
硬脂酸镁 | 3mg |
制备工艺:(1)将缓释骨架加热至熔融,温度控制60℃~70℃;(2)将过筛后处方量的原料药加入熔融后的缓释骨架材料中搅拌均匀;(3)将熔融混合物冷却,1.2mm整粒;(4)加入处方量的粘合剂、润滑剂混合均匀;(5)压片;(6)称取避光薄膜包衣剂(胃溶型),并分别溶解于处方量的蒸馏水中,混合均匀形成包衣液,素片置包衣锅内包衣,即得具有复方氨溴特罗缓释片,包衣增重3-5%。
实施例8
制备工艺:(1)将缓释骨架加热至熔融,温度控制80℃~90℃;(2)将过筛后处方量的原料药加入熔融后的缓释骨架材料中搅拌均匀;(3)将熔融混合物冷却,1.2mm整粒;(4)加入处方量的粘合剂、润滑剂混合均匀;(5)压片;(6)称取避光薄膜包衣剂(胃溶型),并分别溶解于处方量的蒸馏水中,混合均匀形成包衣液,素片置包衣锅内包衣,即得具有复方氨溴特罗缓释片,包衣增重3-5%。
实施例9
盐酸氨溴索 | 75mg |
盐酸克仑特罗 | 0.05mg |
巴西棕榈蜡 | 20mg |
十八烷醇 | 30mg |
聚维酮水溶液 | 10mg |
硬脂酸镁 | 3mg |
制备工艺:(1)将缓释骨架加热至熔融,温度控制90℃~100℃;(2)将过筛后处方量的原料药加入熔融后的缓释骨架材料中搅拌均匀;(3)将熔融混合物冷却,1.2mm整粒;(4)加入处方量的粘合剂、润滑剂混合均匀;(5)压片;(6)称取避光薄膜包衣剂(胃溶型),并分别溶解于处方量的蒸馏水中,混合均匀形成包衣液,素片置包衣锅内包衣,即得具有复方氨溴特罗缓释片,包衣增重3-5%。
测试例
①复方氨溴特罗缓释片中盐酸克仑特罗的含量及含量均匀度测定方法
参照高效液相色谱法(中国药典2020年版通则0512)测定。
色谱条件与系统适用性试验:用十八烷基硅烷键合硅胶为填充剂,以1.7%磺基丁二酸钠二辛酯甲醇溶液-水-醋酸(700:300:100)为流动相,检测波长为296nm。理论板数按盐酸克仑特罗峰计算应不得低于1000。
含量取本品10片,研细,精密称取适量,加流动相溶解并定量稀释制成每1ml中约含盐酸克仑特罗1μg的溶液,滤过,精密量取续滤液20μl,注入液相色谱仪,记录色谱图;另精密称取盐酸克仑特罗对照品适量,用流动相溶解并定量稀释至每1ml中约含1μg盐酸克仑特罗的溶液,作为对照品溶液,同法测定。按外标法以峰面积计算盐酸克仑特罗的含量,应为标示量的90.0-110.0%。
含量均匀度照含量均匀度检查法(中国药典2020年版通则0941)测定
取本品10片,分别置于50ml量瓶中,加流动相溶解并定容至刻度,滤过,续滤液即为供试品溶液。精密量取供试品溶液20μl注入液相色谱仪,记录色谱图,对照品溶液配制见含量项下,同法测定。根据峰面积计算盐酸克仑特罗的含量均匀度,A+2.2S应≤15.0。
②复方氨溴特罗缓释片中盐酸氨溴索的含量及含量均匀度测定方法
参照高效液相色谱法(中国药典2020年版通则0512)测定。
色谱条件与系统适用性试验:用十八烷基硅烷键合硅胶为填充剂,以0.01mol/L磷酸氢二铵溶液(用磷酸调节pH值至7.0)-乙腈(50:50)为流动相;检测波长为248nm。理论板数按盐酸氨溴索峰计算应不低于3000。
含量取盐酸克仑特罗含量项下的细粉,精密称取适量,加流动相溶解并定量稀释制成每1ml中约含盐酸氨溴索30μg的溶液,滤过,精密量取续滤液20μl,注入液相色谱仪,记录色谱图。另精密称取盐酸氨溴索对照品适量,加流动相溶解并定量稀释至每1ml中约含盐酸氨溴索30μg的溶液,同法测定。按外标法以峰面积计算盐酸氨溴索的含量,应为标示量的95.0-105.0%。
含量均匀度照含量均匀度检查法(中国药典2020年版通则0941)测定取本品10片,中分别置于50ml量瓶中,加流动相溶解并定容至刻度,滤过,用移液管精密移取1ml续滤液至50ml量瓶,加流动性定容至刻度,摇匀,即得供试品溶液。精密量取供试品溶液20μl注入液相色谱仪,记录色谱图,对照品溶液配制见含量项下,同法测定。根据峰面积计算盐酸克仑特罗的含量均匀度,A+2.2S应≤15。
③复方氨溴特罗缓释片中盐酸氨溴索和盐酸克仑特罗的溶出度测定方法
溶出度测定法:取本品,参照溶出度与释放度测定法(中国药典2020版二部通则0931)
酸中溶出行为
溶出条件桨法,取6片药片,以1000ml氯化钠盐酸溶液(取氯化钠2g,加水适量溶解,加盐酸7ml,用水稀释至1000ml,pH值为1.2)为溶出介质,转速为每分钟50转,依法操作,经1小时取样。
供试品溶液:取溶出液适量,滤过,取续滤液,作为用于盐酸氨溴索酸中溶出度测定的供试品A1,用于盐酸克仑特罗溶出度测定作为供试品K1。
对照品溶液:取盐酸氨溴索对照品适量,精密称定,加溶出介质溶解并定量稀释制成每1ml中约含75μg的溶液,作为盐酸氨溴索对照溶液A1。取克仑特罗对照品适量,精密称定,加溶出介质溶解并定量稀释制成每1ml中约含0.05μg的溶液,作为盐酸克仑特罗对照溶液K1。
缓冲液中溶出行为
溶出条件桨法,取6片药片,酸中溶出量项下1小时取样后,随即换成以1000ml磷酸盐缓冲液(取磷酸二氢钾6.805g,加1mol/L氢氧化钠溶液22.4ml,加水稀释至1000ml,pH值为6.8)为溶出介质,继续按照酸中溶出法操作,并连续记时,经4、6、8、12、16、20和24小时时分别取溶液5ml滤过,并及时在操作容器中补充释放介质5ml。续滤液即为供试品溶液A2和供试品溶液K2,后续取样点依次命名。
对照品溶液的配置参见酸中溶出测定中对照品的配置。
参照高效液相色谱法(中国药典2020年版通则0512)测定。
盐酸氨溴索色谱条件与系统适用性试验:同盐酸氨溴索含量项。
盐酸克仑特罗色谱条件与系统适用性试验:同盐酸克仑特罗含量项。
测定法照参照高效液相色谱法(中国药典2020年版通则0512),采用盐酸氨溴索色谱条件与系统适用性试验,精密移取20μl的供试品溶液A1和A2、对照溶液A1,注入液相色谱仪,记录盐酸氨溴索的色谱图,计算缓释片中盐酸氨溴索不同时间点的溶出量。照参照高效液相色谱法(中国药典2020年版通则0512),采用盐酸克仑特罗色谱条件与系统适用性试验,精密移取20μl的供试品溶液K1和K2,对照品溶液K1,注入液相色谱仪,记录盐酸克仑特罗的色谱图,计算缓释片中盐酸克仑特罗不同时间点的溶出量。
实施例1-9缓释片的含量及含量均匀度结果、累计溶出度测定结果见表1和表2,可见采用缓释材料熔融制粒工艺能明显延缓活性成分的释放同时解决制剂中盐酸克仑特罗混合不均匀的问题。选择合适的缓释材料能使二种活性成分的释放速度比较一致,且达到24小时释放完全。总之,本发明的药物缓慢释放,可以减少患者服药次数,提高顺应性。
表1含量及含量均匀度结果
表2累计溶出度测定结果
Claims (9)
1.一种复方氨溴特罗缓释片,其素片组成成分按重量份数计包括以下组分:75份盐酸氨溴索、0.05份盐酸克仑特罗、40~60份缓释骨架、8~12份粘合剂和2.7~3.3份润滑剂。
2.根据权利要求1所述的复方氨溴特罗缓释片,其特征在于,其素片组成成分按重量份数计包括以下组分:75份盐酸氨溴索、0.05份盐酸克仑特罗、50份缓释骨架、10份粘合剂和3份润滑剂。
3.根据权利要求1所述的复方氨溴特罗缓释片,其特征在于,所述的缓释骨架选自羟丙甲纤维素、聚维酮、乙基纤维素、甲基纤维素、羟乙基纤维素、十六烷醇、十八烷醇、山榆酸甘油酯、硬脂酸、单硬脂酸、甘油酯、巴西棕榈蜡、羧甲基纤维素钠、聚乙烯醇、甲壳素壳多糖中的一种或多种组合;优选地,所述的缓释骨架选自羟丙甲纤维素、乙基纤维素、巴西棕榈蜡或十八烷醇中的一种或多种组合。
4.根据权利要求1所述的复方氨溴特罗缓释片,其特征在于,所述的粘合剂选自甲基纤维素、乙基纤维素、羟丙纤维素、羟丙甲纤维素、聚维酮或淀粉的一种或多种组合;优选地,所述的粘合剂选自聚维酮。
5.根据权利要求1所述的复方氨溴特罗缓释片,其特征在于,所述的润滑剂选自硬脂酸、氢化植物油、山嵛酸甘油酯、聚乙二醇4000、聚乙二醇6000、硬脂酸镁、月桂醇硫酸镁、滑石粉或微粉硅胶中的一种或多种组合;优选地,所述的润滑剂选自硬脂酸镁。
7.权利要求1所述的缓释片的制备方法,其包括以下步骤:
(1)将缓释骨架加热至熔融,温度控制60℃~100℃;
(2)将过筛后处方量的原料药加入熔融后的缓释骨架材料中搅拌均匀;
(3)将熔融混合物冷却,1.2mm筛网整粒;
(4)加入处方量的粘合剂、润滑剂混合均匀;
(5)压片;
(6)具有避光的薄膜包衣剂包衣。
8.根据权利要求7所述的制备方法,其特征在于,所述步骤(1)中温度控制在90℃~100℃。
9.权利要求1所述的缓释制剂的另一种制备方法,其包括以下步骤:
1)将粘合剂配制成水溶液中,备用;
2)将处方量的盐酸氨溴索、盐酸克仑特罗和缓释骨架等量递增方式混合均匀,于湿法制粒机内边搅拌边加入粘合液,粘合液加入结束后继续制粒1~2min;
3)将制备的软材经18目筛制粒,置于烘箱内40~60℃干燥至水分低于4%;
4)干燥后的颗粒经24目筛整粒;
5)加入处方量的硬脂酸镁,混合均匀;
6)压片;
7)具有避光的薄膜包衣剂包衣。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211264219.3A CN115531337B (zh) | 2022-10-17 | 2022-10-17 | 一种复方氨溴特罗缓释片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211264219.3A CN115531337B (zh) | 2022-10-17 | 2022-10-17 | 一种复方氨溴特罗缓释片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115531337A true CN115531337A (zh) | 2022-12-30 |
CN115531337B CN115531337B (zh) | 2024-01-26 |
Family
ID=84735320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211264219.3A Active CN115531337B (zh) | 2022-10-17 | 2022-10-17 | 一种复方氨溴特罗缓释片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115531337B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060153915A1 (en) * | 2003-01-23 | 2006-07-13 | Amorepacific Corporation | Sustained-release preparations and method for producing the same |
CN101288658A (zh) * | 2008-05-16 | 2008-10-22 | 北京正大绿洲医药科技有限公司 | 复方氨溴索缓释滴丸及其制备方法 |
CN102772395A (zh) * | 2011-05-09 | 2012-11-14 | 中国人民解放军军事医学科学院毒物药物研究所 | 含有盐酸氨溴索和盐酸克仑特罗的缓释制剂及其制备方法 |
-
2022
- 2022-10-17 CN CN202211264219.3A patent/CN115531337B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060153915A1 (en) * | 2003-01-23 | 2006-07-13 | Amorepacific Corporation | Sustained-release preparations and method for producing the same |
CN101288658A (zh) * | 2008-05-16 | 2008-10-22 | 北京正大绿洲医药科技有限公司 | 复方氨溴索缓释滴丸及其制备方法 |
CN102772395A (zh) * | 2011-05-09 | 2012-11-14 | 中国人民解放军军事医学科学院毒物药物研究所 | 含有盐酸氨溴索和盐酸克仑特罗的缓释制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN115531337B (zh) | 2024-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106370757B (zh) | 枸橼酸托法替布片剂药物组合物及质控方法 | |
CN107951853B (zh) | 一种盐酸普拉克索缓释药物组合物及其制备方法 | |
CN107669683B (zh) | 含有西格列汀与二甲双胍的药物组合物 | |
EP3981399A1 (en) | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor | |
CN105213346B (zh) | 一种含有盐酸西那卡塞的药物组合物及其制备方法 | |
CN106389371A (zh) | 枸橼酸托法替布药物组合物 | |
CN112220770B (zh) | 司来帕格的药物组合物及其制备方法 | |
CN104758265B (zh) | 一种雷诺嗪缓释片药物组合物及其制备方法 | |
CN114288257A (zh) | 一种马来酸氟伏沙明片剂及其制备方法 | |
CN110833531A (zh) | 一种维生素e制剂及其制备方法 | |
CN102764254B (zh) | 一种左乙拉西坦药物组合物及其制备方法 | |
CN102772395A (zh) | 含有盐酸氨溴索和盐酸克仑特罗的缓释制剂及其制备方法 | |
CN112933061A (zh) | 一种盐酸阿比多尔胶囊及其制备方法 | |
CN115531337A (zh) | 一种复方氨溴特罗缓释片及其制备方法 | |
CN107496369B (zh) | 一种胞磷胆碱钠片及其粉末直接压片制备方法 | |
CN106214646B (zh) | 一种水飞蓟宾葡甲胺制剂 | |
CN112472675B (zh) | 司来帕格片剂及其制备方法 | |
CN112245402A (zh) | 一种吲达帕胺片及其制备方法 | |
CN115120566A (zh) | 一种含瑞格列奈的口服药物制剂 | |
CN106580909B (zh) | 一种含有盐酸沙格雷酯固体药物组合物 | |
CN113855640B (zh) | 治疗精神疾病的固体药物组合物 | |
CN103494818A (zh) | 一种烟酸辛伐他汀缓释片及其制备方法 | |
CN106474084B (zh) | 一种盐酸普拉克索缓释制剂及其制备方法 | |
CN112076163B (zh) | 一种醋酸巴多昔芬片的药物组合物及其制备方法 | |
CN111481514B (zh) | 一种治疗高血脂的片剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |